Electronic Decision Aid for Pancreatic Adenocarcinoma

Massachusetts General Hospital, Boston, MA
Targeting 2 different conditionsElectronic Decision Aid +1 moreN/ARecruitingLed by Daniel C. Chung, MDResearch Sponsored by Massachusetts General Hospital

Study Summary

This trial will compare how effective an electronic decision aid tool is versus a traditional genetic counselor session for people with ovarian or pancreatic cancer.

Eligible Conditions
  • Pancreatic Adenocarcinoma
  • Ovarian Cancer


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~initial recorded recommendation/referral for genetic testing until the date of sample collection, assessed up to 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and initial recorded recommendation/referral for genetic testing until the date of sample collection, assessed up to 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Average change in knowledge survey score
Decisional Conflict Scores
Shared Decision Making Process Scores
Secondary outcome measures
Average Duration of Decision Making Process
Average time between genetic testing recommendation and sample collection
Percentage of participants choosing genetic testing
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Electronic decision aid armExperimental Treatment1 Intervention
Receive decision aid followed by an appointment with their oncologist.
Group II: Genetic counselor ArmActive Control1 Intervention
Receive pretest counseling with a genetic counselor.

Find a site

Who is running the clinical trial?

Massachusetts General HospitalLead Sponsor
2,814 Previous Clinical Trials
13,564,962 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,369 Previous Clinical Trials
41,214,915 Total Patients Enrolled
Daniel C. Chung, MDPrincipal Investigator
Massachusetts General Hospital

Media Library

Electronic Decision Aid Clinical Trial Eligibility Overview. Trial Name: NCT05470920 — N/A
Pancreatic Adenocarcinoma Research Study Groups: Electronic decision aid arm, Genetic counselor Arm
Pancreatic Adenocarcinoma Clinical Trial 2023: Electronic Decision Aid Highlights & Side Effects. Trial Name: NCT05470920 — N/A
Electronic Decision Aid 2023 Treatment Timeline for Medical Study. Trial Name: NCT05470920 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many people are being granted access to this experiment?

"Yes, this is an active trial recruiting 350 patients from 2 sites, as recent as September 28th, 2022."

Answered by AI

What are the goals that investigators hope to achieve with this clinical trial?

"The aim of this study is to compare the average change in knowledge scores among participants after a genetics session. Other outcomes that will be measured include the percentage of participants who choose to get genetic testing after the educational intervention, the ratio of participants who choose the small, intermediate, or broad testing panel, and the average time it takes between being recommended for genetic testing and having a sample collected."

Answered by AI
~233 spots leftby Oct 2025